The world needs better pain treatments


Pain is widely considered the biggest problem in medicine today: a 2011 market research report indicates that more than 1.5 billion people worldwide suffer from chronic pain,1 more than 21% of who suffer for more than 20 years.2 Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.

1 Global Industry Analysts, Inc. (2011) Global Pain Management Market to Reach US$60 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. [Online] Available from: http://www.prweb.com/pdfdownload/8052240.pdf [Accessed 14 April 2018].
2 Langley P.C.: The prevalence, correlates and treatment of pain in the European Union. CMRO. 2011;463-480

“Imagine going through your daily life where everything that you touch, or that touches you, where most every noise around you from a passing car to children playing, causes you pain. We will leave no stone unturned to help these patients.”

Gabriel Baertschi

Chief Executive Officer

Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.

 

Our ambition

By 2022, we will be a €2bn entrepreneurial, science-based company, specializing in pain, gout and beyond and deliver five new medicines to patients with diseases with high unmet needs. We are turbo-charging our delivery from our own research and collaborating with external partners.

 

Our strategy: leading with innovation

We focus our R&D activities on pain and have built up our portfolio with projects “Beyond Pain” and medical devices. This diversifies our risks and opens new markets for us.

 

“As a worldwide leader in pain management, we are looking for strategic partnerships in research and development to bring innovative solutions to patients with indications with high unmet medical needs. Innovation is at our core and as a fully integrated pharmaceutical company, we can offer support along the whole value chain – from drug development to commercialisation.”

Gabriel Baertschi

Chief Executive Officer

 
Get to know us

Grünenthal Pharma Ltd. is a wholly owned subsidiary of Grünenthal GmbH which distributes and markets pain and anti-infective products under an exclusive distribution agreement with Grünenthal GmbH.

Our aim is to create a highly respected Pharmaceutical Company in Ireland through introductions of our own research and development products and acquired brands.

Grünenthal Pharma Limited markets Zydol® (tramadol HCI), Zydol SR®, Ixprim®, Ixprim Effervescent®, Versatis®, Palexia Film Coated Tablets® and Palexia SR®.

Our vision is to become the preferred partners for our customers, providers and employees by delivering all that we promise.

Grünenthal by the numbers

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 30 countries with affiliates in Europe, Latin America and the USA.

Leadership

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.

Current projects

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.


Join us

Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.


Open Innovation: collaboration at the core

We can’t do everything alone, and we have found some excellent partners to share the load. We believe that open collaborations bring together all the expertise that is relevant to develop innovative medicines for patients.

External growth

We are on a strong and solid economic growth path. In the last years, we’ve already made great progress in acquiring external assets and companies. We will continue on this path as it allows us to broaden our portfolio and entrepreneurial basis.

Social Responsibility

Caring for the world around us is a big part of who we are – from a patient’s pain to climate change – we’re committed to doing what we can to tackle these issues, big and small

Global Capabilities

Although firmly rooted in Germany, today we’re very much a growing global business: since spreading our wings beyond Germany in the 1960’s, we have continued to grow steadily.

Pipeline

In our quest to improve the lives of even more patients in need we enrich our expertise in pain management with a complementary diversification into devices and technologies

14/12/2018

Aachen, Germany and Gothenburg, Sweden, 14 December 2018 – Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications. The handheld device enables individualised dosing of oral medicines in micro units, provides support for patient compliance, can be combined with digital solutions and thus significantly improves patients’ safety. The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties.

01/01/0001

01/01/0001

01/01/0001

01/01/0001

01/01/0001

 
External Link:
You are now leaving the Grünenthal (IE) website. You will be re-directed to an external website. Grünenthal Pharma Ltd., Ireland accepts no responsibility for the content of other websites. ... Cancel ... Ok